JP2022546055A5 - - Google Patents
Info
- Publication number
- JP2022546055A5 JP2022546055A5 JP2022513256A JP2022513256A JP2022546055A5 JP 2022546055 A5 JP2022546055 A5 JP 2022546055A5 JP 2022513256 A JP2022513256 A JP 2022513256A JP 2022513256 A JP2022513256 A JP 2022513256A JP 2022546055 A5 JP2022546055 A5 JP 2022546055A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- formula
- alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910820620 | 2019-08-29 | ||
| CN201910820597 | 2019-08-29 | ||
| CN201910820597.7 | 2019-08-29 | ||
| CN201910820620.2 | 2019-08-29 | ||
| PCT/CN2020/112105 WO2021037205A1 (zh) | 2019-08-29 | 2020-08-28 | 化合物和药物缀合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546055A JP2022546055A (ja) | 2022-11-02 |
| JP2022546055A5 true JP2022546055A5 (https=) | 2023-09-05 |
Family
ID=74684158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513256A Ceased JP2022546055A (ja) | 2019-08-29 | 2020-08-28 | 化合物、薬物複合体及びその調製方法と使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230076803A1 (https=) |
| EP (1) | EP4023659A4 (https=) |
| JP (1) | JP2022546055A (https=) |
| CN (1) | CN113891892B (https=) |
| TW (1) | TW202122093A (https=) |
| WO (1) | WO2021037205A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| KR20220011689A (ko) | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP4396193A4 (en) | 2021-08-30 | 2025-07-02 | Hongene Biotech Corp | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES |
| JP2024546585A (ja) | 2021-12-15 | 2024-12-26 | ホンジーン バイオテック コーポレイション | 官能基化ｎ－アセチルガラクトサミンアナログ |
| WO2024099316A1 (zh) * | 2022-11-08 | 2024-05-16 | 南京明德新药研发有限公司 | 含七元杂环的四价缀合基团及其应用 |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| EP4683666A1 (en) * | 2023-03-23 | 2026-01-28 | ModernaTX, Inc. | Peg targeting compounds for delivery of therapeutics |
| WO2025028656A1 (ja) * | 2023-08-02 | 2025-02-06 | 日東電工株式会社 | オリゴヌクレオチドを製造する方法 |
| CN119799705B (zh) * | 2024-07-08 | 2025-12-12 | 杭州天龙药业有限公司 | 靶向调控HBV基因表达的siRNA及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CN102083983B (zh) * | 2008-08-01 | 2014-04-16 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
| WO2011154331A1 (en) * | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| EP2912045A4 (en) * | 2012-10-29 | 2016-07-13 | Molecular Transfer Inc | POLYCATION METHYL PHOSPHOLIPIDES FOR IMPROVED RELEASE OF NUCLEIC ACIDS IN EUKARYOTIC CELLS |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| CN105452465B (zh) * | 2013-07-31 | 2019-06-21 | 奇比艾企业有限公司 | 鞘脂-聚烷基胺-寡核苷酸化合物 |
| CA2950960A1 (en) * | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| CN107849567B (zh) * | 2015-06-26 | 2024-07-23 | 苏州瑞博生物技术股份有限公司 | 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用 |
| CN120330183A (zh) * | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3065523A1 (en) * | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP2020522510A (ja) * | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| AU2018394875B2 (en) * | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
-
2020
- 2020-08-28 US US17/639,063 patent/US20230076803A1/en not_active Abandoned
- 2020-08-28 CN CN202080032571.7A patent/CN113891892B/zh active Active
- 2020-08-28 JP JP2022513256A patent/JP2022546055A/ja not_active Ceased
- 2020-08-28 TW TW109129461A patent/TW202122093A/zh unknown
- 2020-08-28 EP EP20856439.3A patent/EP4023659A4/en not_active Withdrawn
- 2020-08-28 WO PCT/CN2020/112105 patent/WO2021037205A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546055A5 (https=) | ||
| Uehara et al. | Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated siRNA | |
| JP7662216B2 (ja) | 複合体及びその調製方法と使用 | |
| McClorey et al. | An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies | |
| Heemskerk et al. | In vivo comparison of 2′‐O‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping | |
| AU2017200365C1 (en) | Compositions and methods for modulating apolipoprotein c-iii expression | |
| Rupaimoole et al. | MicroRNA therapeutics: towards a new era for the management of cancer and other diseases | |
| Godeau et al. | Lipid-conjugated oligonucleotides via “click chemistry” efficiently inhibit hepatitis C virus translation | |
| JP2022501059A5 (https=) | ||
| JP2021503940A5 (https=) | ||
| CA2663601C (en) | Duplex oligonucleotide complexes and methods for gene silencing by rna interference | |
| US20250312422A1 (en) | Compositions and methods for facilitating delivery of synthetic nucleic acids to cells | |
| JP2022533841A5 (https=) | ||
| Sharma et al. | Novel cluster and monomer-based GalNAc structures induce effective uptake of siRNAs in vitro and in vivo | |
| BR112016022855B1 (pt) | Compostos e composições para modular a expressão de pkk e seus usos | |
| Kiviniemi et al. | Utilization of intrachain 4′-C-azidomethylthymidine for preparation of oligodeoxyribonucleotide conjugates by click chemistry in solution and on a solid support | |
| JP2022535708A5 (https=) | ||
| RS63778B1 (sr) | Nukleinske kiseline za inhibiranje eksprimiranja lpa u ćeliji | |
| JP2022533419A5 (https=) | ||
| JP2025038097A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| US20200108089A1 (en) | Gemcitabine Derivatives for Cancer Therapy | |
| EP2125029B1 (en) | Construction and use of transfection enhancer elements | |
| Ren et al. | Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential | |
| Wang | Poly (ethylene) Glycol-Based Bottlebrush Polymers as Nanocarriers for Oligonucleotide Therapeutics: Design, Synthesis, and Applications | |
| WO2024255748A1 (zh) | 靶向17-β-羟基类固醇脱氢酶13的核酸及其用途 |